897P - Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab Expanded Access Program (E...

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Renal Cell Cancer
Geriatric Oncology
Cancer Immunology and Immunotherapy
Cancer in Special Situations
Genitourinary Cancers
Presenter roberto sabbatini
Citation Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371
Authors R. sabbatini1, L. Galli2, S. Pignata3, G. Lo Re4, F. Valcamonico5, C. Defferrari6, M. Spada7, D. Santini8, C. Masini9, L. Ciuffreda10, E.M. Ruggeri11, A. Chioni12, L. Livi13, D. Fagnani14, A. Bonetti15, L. Giustini16, S. Duranti17, G. Procopio18, C. Caserta19, G. Cartenì20
  • 1Oncology, AOU Policlinico, 41100 - Modena/IT
  • 2Oncology, AOU Pisana Istituto Toscano Tumori, Pisa/IT
  • 3Irccs, Fondazione G. Pascale, 80131 - Napoli/IT
  • 4Ao, Santa Maria degli Angeli, 41125 - Pordenone/IT
  • 5Asst, Spedali Civili di Brescia, Brescia/IT
  • 6Oncology, Ospedali Galliera, Genova/IT
  • 7Oncology, Fondazione Istituto Giglio, Cefalù/IT
  • 8Oncology, Campus Bio-Medico, 128 - Roma/IT
  • 9Irccs, AO Arcispedale Santa Maria Nuova, 42100 - Reggio Emilia/IT
  • 10Oncology, Città della salute e della Scienza, Torino/IT
  • 11Oncology, Ospedale Belcolle, Viterbo/IT
  • 12Oncology, USL 9 Presidio Ospedaliero Misericordia, Grosseto/IT
  • 13Radiotherapy, AOU Careggi, Firenze/IT
  • 14Oncology, ASST, Vimercate/IT
  • 15Oncology, Ospedale Mater Salutis, 37045 - Legnago/IT
  • 16Uoc, Oncologia Area Vasta 4, Fermo/IT
  • 17Oncology, Azienda ASL8, Arezzo/IT
  • 18Fondazione Irccs, Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 19Oncology, AO S.ta Maria, 5100 - Terni/IT
  • 20Oncology, A.O. A. Cardarelli, 80131 - Napoli/IT

Abstract

Background

The risk of developing renal cell carcinoma (RCC) increases with age, and given the constant gain in life expectancy of the general population, RCC is frequently observed in the elderly. More than 80% of cancer pts aged ≥ 70 years have at least one comorbidity requiring treatment, leaving them exposed to drug interactions. Due to high frequency of comorbidities, these pts are often under-represented in clinical trials. The purpose of this analysis is to evaluate the feasibility of treatment with nivolumab in the elderly (≥ 70 years) and very elderly (≥ 75 years) in the EAP in Italy, given a more realistic picture of real world setting.

Methods

Nivolumab was available upon physician request for pts aged ≥18 years who had relapsed after at least one prior systemic treatment in the advanced or metastatic setting. Nivolumab 3 mg/kg was administered intravenously every 2 weeks to a maximum of 24 months. Pts included in the analysis had received ≥ 1 dose of nivolumab and were monitored for adverse events (AEs) using Common Terminology Criteria for Adverse Events.

Results

Of 389 Italian pts with mRCC enrolled in the EAP in Italy 125 pts (32%) had ≥70 years and 70 (18%) had ≥75 years. With a median follow-up of 9.8 months (0.1-16.2) in the elderly population (≥70 years), the disease control rate (DCR) was 58% including 1 patient in complete response (CR), 32 pts in partial response (PR) and 40 patients in stable disease (SD). Regarding the very elderly population (≥75 years), with a median follow-up of 9.8 months (0.1 -14.9), the DCR was 60% including 1 patient with CR, 19 pts with PR and 22 with SD. As of May 2017, 6 and 12 months overall survival (OS) rate were 87.2% and 77.8% respectively in the elderly population. Regarding the very elderly, the 6 and 12 months OS rate was 83.6% and 77.7%, respectively. The safety profile was consistent to what already observed in the general population.

Conclusions

These results suggest that elderly population can benefit from nivolumab treatment with safety results consistent to what previously reported, supporting the use of nivolumab in this subpopulation.

Clinical trial identification

CA209-99M

Legal entity responsible for the study

Sergio Bracarda coordinator Italian RCC EAP Group

Funding

None

Disclosure

All authors have declared no conflicts of interest.